Studies in AD animal models with transplanted melanoma tumors versus immunocompetent controls will not only provide proof-of-concept about the feasibility of using agents such as STAT inhibitors against different diseases but might also establish an experimental approach to facilitate insights into the complex interactions between melanoma and immune cells. This evidence concerns the gene SOAT1 and Alzheimer disease.